Cardiovascular Health Study (CHS)

Note that you will be prompted to log in or register an account

Accession Number
HLB00040025a

Study Type
Epidemiology Study

Collection Type
Open BioLINCC Study See bottom of this webpage for request information

Study Period
June 1988 - May 2009

NHLBI Division
DCVS

Dataset(s) Last Updated
July 11, 2025

Clinical Trial URLs
NCT00005133

Primary Publication URLs
N/A

Related Studies
SHHS

Consent

Commercial Use Data Restrictions Yes

Data Restrictions Based On Area Of Research Yes

Specific Consent Restrictions
Use of data is tiered to (1) CVD-related research only, or (2) unrestricted area of research. Study participants were also given the option to consent to commercial use.

Available Data

The BioLINCC CHS data package includes follow-up data through year 35, events data through 6/30/2015, and many ancillary studies.

Objectives

The Cardiovascular Health Study (CHS) is a study of risk factors for development and progression of CHD and stroke in people aged 65 years and older. The objectives of the Cardiovascular Health Study are to: 1) quantify associations of conventional and hypothesized risk factors with CHD and stroke; 2) assess the associations of non-invasive measures of subclinical disease with the incidence of CHD and stroke; 3) quantify the associations of risk factors with subclinical disease; 4) characterize the natural history of CHD and stroke, and identify factors associated with clinical course; and 5) describe the prevalence and distributions of risk factors, non-invasive measures of subclinical disease, and clinical CHD and stroke.

Background

The study originated in 1988 from the recommendations of an NHLBI workshop on the management of CHD in the elderly. This is the most extensive study undertaken by the NHLBI to study CVD exclusively in an elderly population. Initially funded for six years, it was renewed for a second six year period in 1994 and recently was renewed for continued morbidity and mortality follow-up.

Participants

The 5,888 study participants were recruited from four U.S. communities and have undergone extensive clinic examinations for evaluation of markers of subclinical cardiovascular disease. The original cohort totaled 5,201 participants. A new cohort was recruited in 1992. The 687 participants in the new cohort are predominately African-American and were recruited at three of the four field centers.

Design

The 2,962 women and 2,239 men were examined yearly from 1989 through 1999. The added minority cohort of 256 men and 431 women was examined from 1992 to 1999. Examination components have included medical history questionnaires, measurement of ankle-brachial index, abdominal and carotid ultrasound studies, echocardiograms, ambulatory electrocardiograms, cerebral magnetic resonance imaging, spirometry and retinal photographs over the past decade. The most extensive evaluations were at study entry (baseline) and again in 1992-1993 to assess change in subclinical disease measures. CHS has undertaken extensive follow-up for ascertainment of cardiovascular events including incident claudication, myocardial infarction, congestive heart failure, stroke and death.

Additional Details

Subjects:

There are 5,888 subjects.

Age:

 

Total Subjects

73-74

575

77-78

426

69-70

898

79-80

341

71-72

730

65-66

507

83-84

147

75-76

525

67-68

944

85-86

92

87-89

78

81-82

228

90+

48

Sex:

 

Total Subjects

Female

3,161

Male

2,378

Race:

 

Total Subjects

White

4,659

Black

844

Other

36

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. The BioLINCC Users Guide describes the components of the review process

Material Types:

Serum, Serum (2hr), Plasma (EDTA), Plasma (Citrate), DNA, Urine

Visits (Vials):

Updated 24th April 2026.

 

 

Serum

Serum (2hr)

Plasma (EDTA)

Plasma (Citrate)

DNA

Urine

Total

Visit Year

6553

.

3068

2325

4329

.

16275

2

5

6711

.

401

3259

4874

.

15245

6

.

.

18699

.

948

.

19647

7

4654

.

9773

.

246

.

14673

8

.

.

.

.

39

.

39

9

5211

11469

6260

12471

732

5505

41648

10

.

.

14819

.

1879

.

16698

18

5147

.

2935

.

.

.

8082

Visits (Subjects):

 

Serum

Total number of subjects

Average volume (ml) per subject

Visit Year

4,558

1.44

2

5

4,286

0.78

7

3,477

1.34

9

3,036

0.86

18

1,000

2.59

 

 

Serum (2hr)

Total number of subjects

Average volume (ml) per subject

Visit Year

2,208

2.60

9

 

 

Plasma (EDTA)

Total number of subjects

Average volume (ml) per subject

Visit Year

2,584

1.19

2

5

384

0.54

6

4,021

2.33

7

3,730

1.31

9

2,943

1.06

10

2,827

2.62

18

988

2.97

 

 

Plasma (Citrate)

Total number of subjects

Average volume (ml) per subject

Visit Year

2,317

0.50

2

5

3,252

0.50

9

3,147

1.98

 

 

DNA

Total number of subjects

Average mass (ug) per subject

Visit Year

2,669

46.74

2

5

3,794

50.19

6

943

48.40

7

245

52.47

8

39

43.17

9

731

183.16

10

1,878

63.72

 

 

Urine

Total number of subjects

Average volume (ml) per subject

Visit Year

2,785

17.79

9

 

Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.

Resources Available

Specimens and Study Datasets

Materials Available

Study Documents

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.